Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now later-stage tilt small index

Nasopharyngeal Cancer Recurrent: later-stage trial registry

1 of 1 indexed Nasopharyngeal Cancer Recurrent trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Nasopharyngeal Cancer Recurrent: 1 US clinical trial tracked, 1 recruiting.

Nasopharyngeal Cancer Recurrent is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Coherus Oncology, running 1 of these trials.

Enrollment posture brief

Registry condition nasopharyngeal-cancer-recurrent

OPEN 1 | RECR 100% | LATE 1 | EARLY 0 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Nasopharyngeal Cancer Re (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Nasopharyngeal Cancer Recurrent

Nasopharyngeal Cancer Recurrent lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Nasopharyngeal Cancer Recurrent on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Nasopharyngeal Cancer Recurrent is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 41

Phase Distribution

PhaseTrial count
Phase 4 1

Top Sponsors

Coherus Oncology 1 trials

Named interventions

Most-linked intervention names on Nasopharyngeal Cancer Recurrent records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Toripalimab Drug
1 trials
Gemcitabine Drug
1 trials
Cisplatin Drug
1 trials
Carboplatin Drug
1 trials

US sites by state

Facility locations filed on Nasopharyngeal Cancer Recurrent trials. A trial with sites in several states counts in each.

Wisconsin 1 trials
Pennsylvania 1 trials
Ohio 1 trials
New York 1 trials
Michigan 1 trials
Massachusetts 1 trials
Georgia 1 trials
California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Nasopharyngeal Cancer Recurrent page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Nasopharyngeal Cancer Recurrent trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Coherus Oncology sponsors the most Nasopharyngeal Cancer Recurrent trials on record, review their full trial history before evaluating a specific study. See Coherus Oncology's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Nasopharyngeal Cancer Recurrent condition card totals 1 registered trials; most-linked intervention Toripalimab; top US site state Wisconsin. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.